Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via the Diskus™inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Budesonide/formoterol has an onset of action that is similar to salbutamol and faster than salmeterol/fluticasone in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006
Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008
Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 89s Year: 2004
Lung function and symptom improvements with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient Source: Annual Congress 2010 - Management of airway disease Year: 2010
Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012